Kala Bio (KALA) Net Income (2016 - 2026)
Kala Bio (KALA) posted Net Income of -$1.7 million for Q1 2026, up 84.0% sequentially from -$10.8 million in Q4 2025, and up 84.7% YoY from -$935551.4 in Q1 2025.
Kala Bio (KALA) Net Income (2016 - 2026) Analysis & Trends
Kala Bio has reported Net Income for 11 years, with the latest figure at -$1.7 million in Q1 2026.
- Quarterly Net Income rose 84.7% year-over-year to -$1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$32.2 million (up 25.42% YoY) and the FY2025 annual result came in at -$184.9 million, down 3.61% from the prior year.
- Net Income grew to -$1.7 million in Q1 2026 per KALA's latest filing, from -$10.8 million in the prior quarter.
- Over five years, Net Income peaked at -$1.7 million in Q1 2026 and troughed at -$32.9 million in Q1 2022.
- A 5-year average of -$12.8 million and a median of -$10.8 million in 2025 frame the typical range for Net Income.
- The sharpest annual moves came in 2024 and 2026: Net Income declined 14.54% in 2024, then soared 84.7% in 2026.
- Over 5 years, Net Income stood at -$10.2 million in 2022, then slipped by 3.06% to -$10.5 million in 2023, then climbed by 0.99% to -$10.4 million in 2024, then declined by 4.12% to -$10.8 million in 2025, then soared by 84.0% to -$1.7 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$1.7 million, -$10.8 million, and -$7.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -355.03 Mn |
| 10 | Kala Bio | 9.87 Mn | 9.87 Mn | - | -1.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.73 Mn |
| Dec 31, 2025 | -10.80 Mn |
| Sep 30, 2025 | -7.93 Mn |
| Jun 30, 2025 | -11.70 Mn |
| Mar 31, 2025 | -11.30 Mn |
| Dec 31, 2024 | -10.37 Mn |
| Sep 30, 2024 | -10.90 Mn |
| Jun 30, 2024 | -10.56 Mn |
| Mar 31, 2024 | -12.88 Mn |
| Dec 31, 2023 | -10.48 Mn |
| Sep 30, 2023 | -9.51 Mn |
| Jun 30, 2023 | -10.29 Mn |
| Mar 31, 2023 | -12.48 Mn |
| Dec 31, 2022 | -10.17 Mn |
| Sep 30, 2022 | -15.78 Mn |
| Jun 30, 2022 | -28.11 Mn |
| Mar 31, 2022 | -32.94 Mn |
| Dec 31, 2021 | -48.95 Mn |
| Sep 30, 2021 | -28.27 Mn |
| Jun 30, 2021 | -31.23 Mn |